Latest Biotech News

Roche has entered the antibody-targeted protein degrader space by expanding its C4 Therapeutics collaboration, committing $20 million upfront for two oncology targets and more than $1 billion in...

Sidewinder Therapeutics emerged from stealth with an oversubscribed $137 million Series B, pitching a bispecific ADC approach designed to improve tumor targeting while reducing toxicities. The San...

Gilead agreed to acquire ADC specialist Tubulis in a deal valued at up to $5 billion, following multiple large transactions since late February. The acquisition includes $3.15 billion upfront plus...

Avalyn Pharma filed for an IPO to fund late-stage development of inhaled reformulations of approved pulmonary fibrosis drugs. The Cambridge-based company plans to move AP01 (inhaled pirfenidone)...

Biogen strengthened the clinical case for BDCA2 as a therapeutic target in cutaneous lupus erythematosus after a second Phase II success for litifilimab (an investigational anti-BDCA2 therapy)....

Dynamic42 and EPO (Experimental Pharmacology and Oncology) announced a collaboration to bring organ-on-chip platforms earlier into preclinical glioblastoma workflows. The partners will pair...

23andMe reported new genetic findings tied to outcomes and side effects from GLP-1 receptor agonist therapies. In a Nature study, investigators analyzed 27,885 research-consented participants and...

Grail expanded access to its Galleri multi-cancer early detection test by partnering with Epic to integrate test ordering directly into Epic’s electronic health record workflows. Clinicians using...

Neurocrine agreed to acquire Soleno Therapeutics for $2.9 billion, expanding its commercial portfolio in endocrinology and rare disease. The deal includes cash consideration of $53.00 per share,...

Amplia Therapeutics halted enrollment in its Phase II Amplicity trial for advanced pancreatic cancer after three dose-limiting toxicities tied to the modified FOLFIRINOX regimen combined with...

Gilead Sciences has agreed to acquire German ADC specialist Tubulis for up to $5 billion, seeking to expand its antibody-drug conjugate platform with new linker and payload technologies. The deal...

Jeito Capital, a prominent European biopharma investor, closed its second independent fund at more than €1 billion (about $1.2 billion), topping its target and raising the firm’s AUM to €1.6...

Sidewinder Therapeutics, a San Diego startup focused on next-generation antibody-drug conjugates, raised an oversubscribed $137 million Series B led by OrbiMed and backed by other major investors....

Biotech policy groups escalated their critique of U.S. drug pricing frameworks after BIO’s March Coffee Chat highlighted how price controls can increase costs for some patients even when nominal...

Avalyn Pharma filed for an IPO as it prepares to move inhaled pulmonary fibrosis assets into Phase 3. The Cambridge, Massachusetts-based biotech’s lead program, AP01, is an inhaled formulation of...

Waters received FDA 510(k) clearance for the BD Onclarity HPV Self-Collection Kit and BD Onclarity HPV Assay, enabling HPV screening through at-home specimen collection. The company said the...

Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, adding Vykat XR (diazoxide choline) to bolster its marketed endocrinology and rare disease franchise. The transaction...

The FDA’s 2027 budget proposal would make the rare pediatric disease priority review voucher program permanent and introduce a new “clinical trial notification pathway” to ease entry into Phase 1...

Research at The University of Texas MD Anderson Cancer Center identified DPY30 as a key epigenetic regulator that maintains genomic stability during replication stress in pancreatic tumors,...

Grail partnered with Epic to embed ordering for its Galleri multi-cancer early detection test directly into Epic’s electronic health record platforms. The collaboration is designed to reduce...